Clinical Trial

Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 20, 2023 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of lenvatinib, tislelizumab combined with RALOX regimen HAIC in advanced hepatocellular carcinoma.
Trial Details
NCT Number NCT05954897
Lead Sponsor Guangdong Provincial People's Hospital
Conditions Hepatocellular Carcinoma
Enrollment 29 participants
Start Date 2023-09-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2023-07-20